Equities Analysts Issue Forecasts for GYRE Q3 Earnings

Key Points

• Noble Financial analysts project that Gyre Therapeutics will achieve earnings per share of $0.03 in Q3 2025, with further estimates indicating $0.05 EPS for Q4 2025 and $0.51 EPS for FY2026.
• Gyre Therapeutics recently reported Q2 earnings of $0.02 EPS, missing estimates, with a revenue of $26.77 million falling short of the consensus of $30.80 million.
• The stock received a "buy" rating from HC Wainwright, with a target price set at $18.00, supported by a consensus rating of "Buy" from multiple analysts.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Noble Financial issued their Q3 2025 earnings per share (EPS) estimates for Gyre Therapeutics in a note issued to investors on Tuesday, September 9th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings of $0.03 per share for the quarter. Noble Financial also issued estimates for Gyre Therapeutics' Q4 2025 earnings at $0.05 EPS, FY2025 earnings at $0.09 EPS and FY2026 earnings at $0.51 EPS.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $26.77 million for the quarter, compared to the consensus estimate of $30.80 million. Gyre Therapeutics had a return on equity of 7.67% and a net margin of 4.08%.

Separately, HC Wainwright initiated coverage on Gyre Therapeutics in a report on Tuesday, August 26th. They set a "buy" rating and a $18.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $18.00.

Gyre Therapeutics Stock Performance

Shares of NASDAQ:GYRE traded down $0.05 during midday trading on Thursday, hitting $7.86. 14,291 shares of the stock were exchanged, compared to its average volume of 158,333. The stock has a market capitalization of $756.52 million, a price-to-earnings ratio of 786.29 and a beta of 1.86. The business's 50-day moving average price is $7.62 and its 200 day moving average price is $8.52. Gyre Therapeutics has a 12 month low of $6.11 and a 12 month high of $19.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GYRE. Wells Fargo & Company MN raised its position in shares of Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after buying an additional 913 shares in the last quarter. Barclays PLC grew its holdings in Gyre Therapeutics by 13.5% in the 4th quarter. Barclays PLC now owns 10,543 shares of the company's stock worth $128,000 after acquiring an additional 1,255 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock worth $46,000 after purchasing an additional 1,402 shares during the period. GAMMA Investing LLC lifted its position in shares of Gyre Therapeutics by 15,083.3% in the 1st quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock worth $140,000 after purchasing an additional 1,810 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Gyre Therapeutics by 18.7% in the 1st quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company's stock worth $127,000 after purchasing an additional 2,596 shares during the period. Institutional investors own 23.99% of the company's stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.